Literature DB >> 27065581

Analyzing Relationship Between Monoclonal Gammopathy of Undetermined Significance (MGUS) with Different Types of Neuropathy: An Observational Study.

Shahzaib Nabi1, Pushpinderdeep Kahlon1, Farshid Bozorgnia2, Adeel Arshad3, Akmam Saleem4, Philip Kuriakose5.   

Abstract

To analyze multiple variables, including immunoglobulin subtypes in patients with monoclonal gammopathy of undetermined significance (MGUS) and different types of neuropathy. This was a retrospective, single center study done in a tertiary care hospital in the United States. The data was collected for years 2001-2011. Inclusion criteria were the presence of MGUS and neuropathy. Exclusion criteria were the presence of other factors such as diabetes, vitamin B12 deficiency, alcoholism etc. which can cause neuropathy. Patients with IgM MGUS were compared with patients having Non-IgM MGUS. A total of 281 patients were analyzed in this study. The average age at the time of diagnosis of MGUS and neuropathy was 68 years. The most common type of neuropathy was sensorimotor peripheral neuropathy (46 %). The most common location of neuropathy was the lower extremities (68 %). Among our patients, 52 % had their neuropathy symptoms for 1-5 years before presenting to the clinic. When IgM MGUS was compared with Non-IgM MGUS, a statistically significant difference was found in terms of race (White vs. Others, OR 4.43, 95 % CI 2.13, 9.19, p < 0.001) and survival status (OR 1.98, 95 % CI 1.01, 3.90, p = 0.046). Patients with MGUS are prone to develop different types of neuropathies. Caucasians are more likely to have IgM MGUS as compared to other races. IgM MGUS is generally related to worse outcomes as compared to Non-IgM MGUS. Medical therapies, including gabapentin and pregabalin are effective treatments and the response rate can be as high as 80-90 % with these medications.

Entities:  

Keywords:  Gabapentin; Monoclonal gammopathy of undetermined significance; Neuropathy; Pregabalin

Year:  2015        PMID: 27065581      PMCID: PMC4789005          DOI: 10.1007/s12288-015-0547-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

Review 1.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael P T Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.

Authors:  Brendan M Weiss; Alex Minter; Jude Abadie; Robin Howard; Joao Ascencao; Geraldine P Schechter; Michael Kuehl; Ola Landgren
Journal:  Am J Hematol       Date:  2011-05-04       Impact factor: 10.047

3.  Comparison of IgM-MGUS and IgG-MGUS polyneuropathy.

Authors:  D Simovic; K C Gorson; A H Ropper
Journal:  Acta Neurol Scand       Date:  1998-03       Impact factor: 3.209

4.  IgM-monoclonal gammopathy neuropathy and tremor: a first epidemiologic case control study.

Authors:  Matthew C Ahlskog; Neeraj Kumar; Michelle L Mauermann; Christopher J Klein
Journal:  Parkinsonism Relat Disord       Date:  2012-04-03       Impact factor: 4.891

5.  Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study.

Authors:  M Théaudin; P Lozeron; C Lacroix; P Chrétien; B Ducot; C Denier; D Adams
Journal:  Rev Neurol (Paris)       Date:  2011-10-22       Impact factor: 2.607

6.  Characterization of neuropathies associated with elevated IgM serum levels.

Authors:  Adina R Goldfarb; Howard W Sander; Thomas H Brannagan; Paul Magda; Norman Latov
Journal:  J Neurol Sci       Date:  2004-12-24       Impact factor: 3.181

7.  [Polyneuropathy associated with monoclonal gammapathy: treatment perspectives].

Authors:  Jean-Marc Leger; Bénédicte Chassande; Francesco Bombelli; Karine Viala; Lucile Musset; Jean Neil
Journal:  Bull Acad Natl Med       Date:  2009-05       Impact factor: 0.144

8.  Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study.

Authors:  J M F Niermeijer; K Fischer; M Eurelings; H Franssen; J H J Wokke; N C Notermans
Journal:  Neurology       Date:  2010-02-02       Impact factor: 9.910

9.  Monoclonal gammopathy: natural history studied with a retrospective approach.

Authors:  Hlif Steingrimsdottir; Vilhelmìna Haraldsdottir; Isleifur Olafsson; Vilmundur Gudnason; Helga M Ogmundsdottir
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

10.  Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases.

Authors:  L Magy; B Chassande; T Maisonobe; P Bouche; J-M Vallat; J-M Léger
Journal:  Eur J Neurol       Date:  2003-11       Impact factor: 6.089

View more
  1 in total

1.  Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy.

Authors:  Michael Fleischer; Inn Lee; Friedrich Erdlenbruch; Lena Hinrichs; Ioannis N Petropoulos; Rayaz A Malik; Hans-Peter Hartung; Bernd C Kieseier; Christoph Kleinschnitz; Mark Stettner
Journal:  J Neuroinflammation       Date:  2021-04-08       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.